Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 2 |
2021 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Primary Myelofibrosis"
Page 1
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.
Blood Adv. 2019 Jun 11;3(11):1729-1737. doi: 10.1182/bloodadvances.2019000211.
Blood Adv. 2019.
PMID: 31175128
Free PMC article.
The relative risk (RR) of thrombosis in the presence of leukocytosis was 1.59 (95% CI, 1.40-1.80), mainly accounted for by ET (RR, 1.65; 95% CI, 1.43-1.91) and arterial thrombosis (RR, 1.45; 95% CI, 1.13-1.86) subgroups; the effect was not significant in venous thrombosis alone. …
The relative risk (RR) of thrombosis in the presence of leukocytosis was 1.59 (95% CI, 1.40-1.80), mainly accounted for by ET (RR, 1.65; 95% …
A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.
Hamulyák EN, Daams JG, Leebeek FWG, Biemond BJ, Te Boekhorst PAW, Middeldorp S, Lauw MN.
Hamulyák EN, et al.
Blood Adv. 2021 Jan 12;5(1):113-121. doi: 10.1182/bloodadvances.2020003628.
Blood Adv. 2021.
PMID: 33570633
Free PMC article.
Patients with myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have an increased risk of thrombosis. Risk of recurrent thrombosis can be reduced with antithrombotic therapy and/or cytoreduction, but …
Patients with myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, ha …
Item in Clipboard
State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019.
McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N.
McLornan DP, et al.
Haematologica. 2019 Apr;104(4):659-668. doi: 10.3324/haematol.2018.206151. Epub 2019 Mar 14.
Haematologica. 2019.
PMID: 30872371
Free PMC article.
Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to an ever-evolving armamentarium of novel agents to treat patients, although allogeneic hematopoietic stem cell tran …
Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating phys …
Item in Clipboard
Cite
Cite